Dr. Marcus Hompesch is Chief Executive Officer and Chairman of the Board of ProSciento and has led the company since its inception in 2003. He is also editor-in-chief of the journal Endocrinology, Diabetes & Metabolism, a Wiley publication. His career and track record in metabolism-focused clinical R&D, spanning more than 25 years in academic and industry settings, includes contributions to clinical development strategies and early phase research studies for many of the diabetes and related metabolic drugs and devices on the market globally.
Prior to leading ProSciento, Dr. Hompesch was Chief Operating Officer of Profil Institut für Stoffwechselforschung GmbH and, before that, was founder and Chief Executive Officer of the medical technology company Med.IQ. He is an author of more than 100 publications, including peer-reviewed journals and editorials and is a regular peer reviewer for scientific journals relevant to metabolic diseases. He is also an editor and co-author of the textbook Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development.
As a licensed physician in Europe he received his M.D. from the University of Düsseldorf, Germany, and following medical school trained in internal medicine and diabetology at the Klinikum Wuppertal Medical Center. He also was a scientific associate at the Department of Medical Informatics, Bio-Statistics and Epidemiology at the Ruhr University Bochum, Germany.
